Immunome, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $48.2M | $49.2M |
| FY2022 | — | $16.7M | $20.3M |
| FY2023 | — | $119.9M | $98.7M |
| FY2024 | — | $181.2M | $143.4M |
| FY2025 | — | $634.3M | $653.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $48.2M | $49.2M |
| FY2022 | — | $16.7M | $20.3M |
| FY2023 | — | $119.9M | $98.7M |
| FY2024 | — | $181.2M | $143.4M |
| FY2025 | — | $634.3M | $653.5M |